



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/02, A01N 37/18		A1	(11) International Publication Number: WO 98/48825 (43) International Publication Date: 5 November 1998 (05.11.98)
<p>(21) International Application Number: PCT/US98/08569</p> <p>(22) International Filing Date: 29 April 1998 (29.04.98)</p> <p>(30) Priority Data: 08/846,881 1 May 1997 (01.05.97) US</p> <p>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 08/846,881 (CON) Filed on 1 May 1997 (01.05.97)</p> <p>(71) Applicant (for all designated States except US): THE SALK INSTITUTE FOR BIOLOGICAL STUDIES [US/US]; 10010 North Torrey Pines Road, La Jolla, CA 90237 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): EVANS, Ronald, M. [US/US]; 1471 Cottontail Lane, La Jolla, CA 92037 (US). NAGY, Laszlo [HU/US]; 12570 Carmel Creek Road #79, San Diego, CA 92130 (US).</p> <p>(74) Agent: REITER, Stephen, E.; Gray Cary Ware & Freidenrich LLP, Suite 1600, 4365 Executive Drive, San Diego, CA 92121 (US).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> <p>(54) Title: COMPOUNDS USEFUL FOR THE MODULATION OF PROCESSES MEDIATED BY NUCLEAR HORMONE RECEPTORS, METHODS FOR THE IDENTIFICATION AND USE OF SUCH COMPOUNDS</p> <p>(57) Abstract</p> <p>In accordance with the present invention, it has discovered that histone deacetylase associates with hormone receptor complexes and contributes to the repression thereof. It has further been discovered that exposure of a repressed system to histone deacetylase inhibitors relieves this repression. Thus, histone deacetylase inhibitors have been found to be useful for the activation of genes responsive to hormone receptors. In accordance with another aspect of the invention, formulations useful for modulation of hormone-mediated processes have been developed. In addition, assays have been developed for the identification of compounds useful to modulate the above-described processes.</p>	

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Compounds Useful for the Modulation of Processes
Mediated by Nuclear Hormone Receptors, Methods for
the Identification and Use of Such Compounds

FIELD OF THE INVENTION

The present invention relates to methods for the modulation of nuclear receptor mediated processes, compounds useful therefor and methods for the identification of such compounds.

BACKGROUND OF THE INVENTION

The actions of steroids, retinoids and thyroid hormones are mediated by intracellular nuclear receptors whose coordinate activity defines the physiological response (Mangelsdorf and Evans, Cell 83:841-850 (1995)). These receptors are all structurally related and constitute a superfamily of nuclear regulatory proteins that modulate gene expression in a ligand-dependent fashion. Previous studies have demonstrated that the 9-cis retinoic acid receptor (RXR) serves as a common heterodimeric partner for thyroid hormone receptor (TR), retinoic acid receptor (RAR), vitamin D receptor (VDR), prostanoids (PPAR), as well as numerous orphan receptors (LeBlanc and Stunnenberg Genes & Dev. 9:1811-1816 (1995)).

Transcriptional repression is an intrinsic part of endocrine physiology and contributes to feedback regulation associated with the inhibition of the physiologic response. Indeed, the thyroid hormone receptor is converted to an oncogene by mutations which block hormone binding and create a constitutive transcriptional repressor (Damm et al. EMBO J. 6:375-382 (1987), Nature 339:593-597 (1989); Graf and Beug Cell 34:7-9 (1983); Sap et al. Nature 340:242-244 (1989)). Multiple studies on transcriptional silencing by verba and the non-liganded

thyroid hormone receptor suggest that repression is required for oncogenesis and that this process is mediated by a diffusible co-factor(s) that associates with the ligand binding domain (LBD) (Baniahmad et al. Mol. Cell. Biol. 15:76-86 (1995); Casanova et al. Mol. Cell. Biol. 14:1756-1765 (1994)).

Transcriptional co-repressors (SMRT and N-CoR) have recently been identified that associate with non-liganded receptors resulting in suppression of basal transcriptional activity (see, for example, Chen and Evans Nature 377:454-457 (1995); Chen et al. PNAS 93:7567-7571 (1996); Horlein et al. Nature 377:397-404 (1995); and Sande and Privalsky Mol. Endo. 10:813-825 (1996)).

While the mechanism of this repression is not known, chromatin remodeling has been suggested to be a component of transcriptional regulation (for review see Wolffe and Pruss. Curr. Biol. 6:234-237 (1996); Felsenfeld Cell 86:13-19 (1996)). Indeed, it has been suggested that specific transcriptional activation may be involved in local changes in chromatin structure. In fact, it has recently been demonstrated that nuclear hormone receptors may utilize the CREB binding protein (CBP) or its homolog p300 (Janknecht and Hunter Nature 383:22-23 (1996)), to function as a nuclear receptor co-factor (Chakravarti, et al. Nature 383:99-103 (1996); Hanstein et al. PNAS 93:11540-11545 (1996); Kamei et al. Cell 85:403-414 (1996); Yao et al. PNAS 93:10626-10631 (1996)). In addition to CBP/p300, multiple hormone-dependent and independent associated co-factors have been characterized (Fondell et al. PNAS 93:8392-8333 (1996)).

Of particular interest is the recent demonstration that CPB/p300 associates with the histone acetylase P/CAF (Yang X-J et al. Nature 382:319-324 (1996)) which displays significant sequence homology to the yeast

transcription activator GCN5, also known to be a histone acetylase (Brownell et al. Cell 84:843-851 (1996)). Further, CBP/p300 harbors intrinsic histone acetyltransferase activity, resulting in alternative or perhaps simultaneous histone acetylation (Ogryzko et al. Cell 87:953-959 (1996)). The notion that multiple transcriptional co-activators possess acetylase activity suggests that their recruitment to a DNA template would locally destabilize nucleosomes creating a permissive state for promoter activation.

Accordingly, there is a need in the art for a further understanding of the interaction(s) between the various components involved in regulation of hormone mediated processes. A clearer understanding of these processes will facilitate the development of methods to modulate hormone mediated processes, as well as assays for the identification of compounds useful for such modulation. These and other needs in the art are addressed by the present invention.

20

BRIEF DESCRIPTION OF THE INVENTION

In accordance with the present invention, we have discovered that histone deacetylase associates with hormone receptor complexes and contributes to the repression thereof. We have further discovered that exposure of a repressed system to histone deacetylase inhibitors relieves this repression. Thus, histone deacetylase inhibitors have been found to be useful for the activation of genes responsive to hormone receptors.

In accordance with another aspect of the invention, formulations useful for modulation of hormone-mediated processes have been developed. In addition, assays have been developed for the identification of compounds useful to modulate the above-described processes.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1(A) provides a schematic representation showing an alignment of SMRT and N-CoR and the boundaries of N- and C-terminal deletion mutants. Hatched boxes indicate the previously identified repressor domains (RD1 and RD2; see Horlein et al., *Nature* 377:397-404 (1995)) and the checkered boxes indicate the location of receptor interaction domains (ID1 and 2; Seol et al., *Mol. Endo.* 10:1646-1655 (1996)). Arrows indicate the location of bacterial protease digestion sites in SMRT. The GAL4-DNA binding domain (DBD) 1-147 (shaded ovals) was fused to the N-terminus of these constructs and increasing amounts (0.02, 0.1, 0.5 µg) were tested in transient transfection assays for repressor activity (% of the basal activity in the presence of GAL4-DBD only). The minimal repressor domains of SMRT (SRD-1 and SRD-2) are shaded. Repression values of 10 fold or higher are boxed.

Figure 1(B) illustrates the interaction of SMRT with mSin3A in yeast. Mean values of at least 6 independent measurements are presented. Also illustrated is a schematic representation of mSin3A with amphipathic helix (PAH) domains (1-4) shown as boxes.

Figure 1(C) diagrams the interaction of mSin3A with SMRT and N-CoR.

Figure 2(A) shows that DNA bound HDAC1 (HDAC-GAL4) is a potent repressor of transcriptional activation, resulting in a 60 fold repression of basal activity.

Figure 2(B) shows the relief of HDAC1 dependent repression by VP-SMRT 38-811.

Figure 2(C) illustrates that full length SMRT (but not SMRT 982-1495) squelches the relieving effect of

VP-SMRT 38-811 on HDAC I dependent transcriptional repression.

Figure 3(A) shows the potentiation of 9-cis retinoic acid (9-cis RA) induced differentiation by the 5 histone deacetylase inhibitor Trichostatin A (TSA). CD14 expression levels of HL-60 cells treated with the indicated amount of Trichostatin A (TSA), 9-cis RA alone or in combination were determined by flow cytometry. The mean fluorescence intensities (FL2) from a representative 10 experiment are presented.

Figure 3(B) illustrates CD11b expression levels on HL-60 cells treated with the indicated amount of TSA or 9-cis RA alone or in combination.

Figure 3(C) diagrams hormonal targeting of 15 nuclear complexes to chromatin template. In the absence of hormone, a SMRT, mSin3A and HDAC1 complex associates with unliganded receptor heterodimers. In this complex, histone deacetylase activity creates a repressed chromatin environment.

20 DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention, there are provided methods for the modulation of hormone mediated processes in a biological system, said method comprising contacting said system with an amount of a histone 25 deacetylase inhibitor effective to modulate said hormone mediated process.

As employed herein, the term "modulate" refers to the ability of a modulator for a member of the steroid/thyroid superfamily to either directly (by binding 30 to the receptor as a ligand) or indirectly (as a precursor for a ligand or an inducer which promotes production of

ligand from a precursor) induce expression of gene(s) maintained under hormone expression control, or to repress expression of gene(s) maintained under such control.

As employed herein, the phrase "hormone mediated processes" refers to biological, physiological, endocrinological, and other bodily processes which are mediated by receptor or receptor combinations which are responsive to the ligands described herein. Modulation of such processes can be accomplished in vitro or in vivo. In vivo modulation can be carried out in a wide range of subjects, such as, for example, humans, rodents, sheep, pigs, cows, and the like.

As employed herein, the phrase "biological system" refers to an intact organism or a cell-based system containing the various components required for response to the ligands described herein, e.g., an isoform of RAR (i.e., RAR α , RAR β or RAR γ), a silent partner for the RAR isoform (e.g., RXR), and an RAR-responsive reporter (which typically comprises an RAR response element (RARE) in operative communication with a reporter gene; suitable reporters include luciferase, chloramphenicol transferase, β -galactosidase, and the like).

Contacting in a biological system contemplated by the present invention can be accomplished in a variety of ways, and the treating agents contemplated for use herein can be administered in a variety of forms (e.g., in combination with a pharmaceutically acceptable carrier therefor) and by a variety of modes of delivery. Exemplary pharmaceutically acceptable carriers include carriers suitable for oral, intravenous, subcutaneous, intramuscular, intracutaneous, and the like administration. Administration in the form of creams, lotions, tablets, dispersible powders, granules, syrups, elixirs, sterile

aqueous or non-aqueous solutions, suspensions or emulsions, and the like, is contemplated.

For the preparation of oral liquids, suitable carriers include emulsions, solutions, suspensions, syrups, 5 and the like, optionally containing additives such as wetting agents, emulsifying and suspending agents, sweetening, flavoring and perfuming agents, and the like.

For the preparation of fluids for parenteral administration, suitable carriers include sterile aqueous 10 or non-aqueous solutions, suspensions, or emulsions. Examples of non-aqueous solvents or vehicles are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl oleate. Such dosage forms may also contain 15 adjuvants such as preserving, wetting, emulsifying, and dispersing agents. They may be sterilized, for example, by filtration through a bacteria-retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the 20 compositions. They can also be manufactured in the form of sterile water, or some other sterile injectable medium immediately before use.

As employed herein, the phrase "effective amount" refers to levels of compound sufficient to provide 25 circulating concentrations high enough to modulate the expression of gene(s) mediated by members of the steroid/thyroid superfamily of receptors. Such a concentration typically falls in the range of about 10 nM up to 2 μ M; with concentrations in the range of about 100 30 nM up to 500 nM being preferred. Since the activity of different compounds described herein may vary considerably, and since individual subjects may present a wide variation in severity of symptoms, it is up to the practitioner to

determine a subject's response to treatment and vary the dosages accordingly.

Histone deacetylase enzymes contemplated for use in the practice of the present invention include HDAC1, 5 Rpd3, and the like.

In a presently preferred aspect of the present invention, a ligand for a member of the steroid/thyroid superfamily of receptors is administered to said system in addition to said histone deacetylase inhibitor.

10 As employed herein, the term "ligand (or ligand precursor) for a member of the steroid/thyroid hormone superfamily of receptors" (i.e., intracellular receptor) refers to a substance or compound which, in its unmodified form (or after conversion to its "active" form), inside a 15 cell, binds to receptor protein, thereby creating a ligand/receptor complex, which in turn can activate an appropriate hormone response element. A ligand therefore is a compound which acts to modulate gene transcription for a gene maintained under the control of a hormone response 20 element, and includes compounds such as hormones, growth substances, non-hormone compounds that modulate growth, and the like. Ligands include steroid or steroid-like compounds, retinoids, thyroid hormones, pharmaceutically active compounds, and the like. Individual ligands may 25 have the ability to bind to multiple receptors.

As employed herein, the phrase "members of the nuclear receptor superfamily" (also known as "members of the steroid/thyroid superfamily of receptors" or "intracellular receptors") refers to hormone binding 30 proteins that operate as ligand-dependent transcription factors, including identified members of the steroid/thyroid superfamily of receptors for which specific ligands have not yet been identified (referred to

hereinafter as "orphan receptors"). These hormone binding proteins have the intrinsic ability to bind to specific DNA sequences. Following binding, the transcriptional activity of target gene (i.e., a gene associated with the specific 5 DNA sequence) is modulated as a function of the ligand bound to the receptor.

The DNA-binding domains of all of these nuclear receptors are related, consisting of 66-68 amino acid residues, and possessing about 20 invariant amino acid 10 residues, including nine cysteines.

A member of the superfamily can be identified as a protein which contains the above-mentioned invariant amino acid residues, which are part of the DNA-binding domain of such known steroid receptors as the human 15 glucocorticoid receptor (amino acids 421-486), the estrogen receptor (amino acids 185-250), the mineralocorticoid receptor (amino acids 603-668), the human retinoic acid receptor (amino acids 88-153). The highly conserved amino acids of the DNA-binding domain of members of the 20 superfamily are as follows:

Cys - X - X - Cys - X - X - Asp* - X -
Ala* - X - Gly* - X - Tyr* - X - X -
X - X - Cys - X - X - Cys - Lys* -
X - Phe - Phe - X - Arg* - X - X - X -
25 X - X - X - X - X - (X - X -) Cys -
X - X - X - X - X - (X - X - X -) Cys -
X - X - X - Lys - X - X - Arg - X - X -
Cys - X - X - Cys - Arg* - X - X -
Lys* - Cys - X - X - X - Gly* - Met
30 (SEQ ID NO:1);

wherein X designates non-conserved amino acids within the DNA-binding domain; the amino acid residues denoted with an asterisk are residues that are almost universally

conserved, but for which variations have been found in some identified hormone receptors; and the residues enclosed in parenthesis are optional residues (thus, the DNA-binding domain is a minimum of 66 amino acids in length, but can 5 contain several additional residues).

Exemplary members of the steroid/thyroid superfamily of receptors include steroid receptors such as glucocorticoid receptor, mineralocorticoid receptor, progesterone receptor, androgen receptor, vitamin D₃ 10 receptor, and the like; plus retinoid receptors, such as RAR α , RAR β , RAR γ , and the like, plus RXR α , RXR β , RXR γ , and the like; thyroid receptors, such as TR α , TR β , and the like; as well as other gene products which, by their 15 structure and properties, are considered to be members of the superfamily, as defined hereinabove. Examples of orphan receptors include the PPARs (e.g., PPAR α , PPAR γ and PPAR δ), HNF4 [see, for example, Sladek et al., in Genes & Development 4: 2353-2365 (1990)], the COUP family of 20 receptors [see, for example, Miyajima et al., in Nucleic Acids Research 16: 11057-11074 (1988), Wang et al., in Nature 340: 163-166 (1989)], COUP-like receptors and COUP homologs, such as those described by Mlodzik et al., in Cell 60: 211-224 (1990) and Ladias et al., in Science 251: 25 561-565 (1991), the ultraspiracle receptor [see, for example, Oro et al., in Nature 347: 298-301 (1990)], and the like.

The retinoic acid receptor (RAR), the thyroid hormone receptor (T₃R), the vitamin D₃ receptor (VDR) and the fatty acid/peroxisome proliferator activated receptor (PPAR), for example, preferentially bind to DNA as 30 heterodimers with a common partner, the retinoid X (or 9-cis retinoic acid) receptor (RXR; see, for example, Yu et al., in Cell 67:1251-1266 (1991); Bugge et al., in EMBO J. 11:1409-18 (1992); Kliewer et al., in Nature 355:446-449 35 (1992); Leid et al., in Cell 68:377-395 (1992); Marks et

al., in EMBO J. 11:1419-1435 (1992); Zhang et al., in Nature 355:441-446 (1992); and Issemann et al., in Biochimie. 75:251-256 (1993).

5 In accordance with another embodiment of the present invention, there are provided compositions comprising:

(a) a ligand for a member of the steroid/thyroid hormone superfamily of receptors, and

10 (b) an inhibitor for co-repressor(s) which interact with said member of the steroid/thyroid hormone superfamily of receptors to suppress basal transcription activity

in a pharmaceutically acceptable carrier therefor.

15 Presently preferred ligands contemplated for inclusion in the above-described compositions are ligands for retinoid receptors (e.g., all-trans retinoic acid, 9-cis retinoic acid, and the like), ligands for thyroid hormone receptors (e.g., thyroid hormone), or ligands for
20 vitamin D₃ receptor (e.g., 1,25-dihydroxy vitamin D), and the like.

Inhibitors contemplated for inclusion in the above-described composition include histone deacetylase inhibitors (e.g., Trichostatin A (TSA), Trapoxin, and the like), chromatin remodeling machinery inhibitors, and the like.

25 In accordance with another embodiment of the present invention, there are provided isolated co-repressor complexes comprising:

30 (i) at least one co-repressor,
(ii) a histone deacetylase, and

(iii) a homodimer or heterodimer of a member of the steroid/thyroid superfamily of receptors.

As employed herein, the phrase "isolated" refers to peptides which have been removed from their native environment, either by enrichment thereof from natural sources, by chemical synthesis, by recombinant production, and the like. Thus, the recombinant expression of the above-described co-repressor complex would produce an "isolated" protein complex, since such expression would produce the peptide in a non-native environment. Similarly, substantial enrichment of the co-repressor complex content of a cell extract would also provide an "isolated" peptide complex.

Co-repressors contemplated by the above-described complexes include co-repressor(s) having a structure and function characteristic of SMRT (i.e., silencing mediator for retinoic acid and thyroid receptors), repressor domains of SMRT (e.g., SRD-1, SRD-2, amino acids 1-981 thereof, and the like), mSin3A, protein-protein interaction domains of mSin3A (e.g., PAH-1, PAH-2, PAH-3, PAH-4, combinations of PAH, and the like), N-CoR, Mad/Mxi-1, mSin3B, Sin3, and the like, as well as combinations of any two or more thereof.

As is known in the art, there are a number of histone deacetylase enzymes known in the art, any of which can be included in the above-described complexes, e.g., HDAC1, Rpd3, and the like.

The co-repressor complex is a critical component of switches which control cell cycle regulation and cancer. For example, co-repressor complexes function as integrators in multiple transcriptional regulatory pathways to control cell growth and differentiation. Transcriptional co-repressors such as SMRT and N-CoR associate with non-liganded receptors resulting in suppression of basal

transcriptional activity (Chen and Evans, 1995; Chen et al, 1996; Horlein et al. 1995; Sande and Privalsky, 1996). In contrast, mSin3A associates with Mad/Mxi-1:Max heterodimers to promote differentiation (Ayer et al. Cell 5 80:767-776 (1995)). Thus, in accordance with the present invention, compounds are contemplated which promote dissociation of the co-repressor complex from hormone receptors (e.g., retinoid and/or thyroid hormone receptors) and further promote association of co-repressor complexes 10 with Mad/Mxi-1 growth inhibitors.

As used herein, the term "homodimer/heterodimer" refers to a homodimeric or heterodimeric form of one or more members of the steroid/thyroid hormone superfamily of receptors, wherein at least one of said members contains a 15 silencing domain which represses basal level promoter activity of target genes. Homodimeric or heterodimeric members of the steroid/thyroid hormone superfamily of receptors contemplated for use herein include thyroid hormone receptor homodimer, thyroid hormone receptor-retinoid X receptor heterodimer, retinoic acid receptor homodimer, retinoic acid receptor-retinoid X receptor heterodimer, retinoid X receptor homodimer, and the like. 20

In accordance with still another embodiment of the present invention, there are provided methods to 25 identify compounds which disrupt complex comprising:

- (i) at least one co-repressor,
- (ii) a histone deacetylase, and
- (iii) a homodimer or heterodimer of a member of the steroid/thyroid superfamily of receptors,

30 said method comprising:

(a) contacting a modified host cell with a test compound, wherein said modified host cell comprises:

5 a first fusion protein comprising a GAL4 DNA binding domain (or, in an alternative embodiment, an activation domain), operatively associated with at least one co-repressor,

10 a second fusion protein comprising an activation domain (or, in an alternative embodiment, a GAL4 DNA binding domain), operatively associated with a histone deacetylase, and

15 a reporter construct comprising a GAL4 response element operatively linked to a reporter gene; and

(b) selecting those test compounds which cause reduced expression of the reporter gene product.

20 As used herein, the term "disrupt" embraces compounds which cause substantially complete disociation of the various components of the complex, as well as compounds which merely alter the conformation of one or more components of the complex so as to reduce the repression
25 otherwise caused thereby.

Any cell line can be used as a suitable "host" for the functional bioassay contemplated for use in the practice of the present invention. Thus, cells contemplated for use in the practice of the present
30 invention include transformed cells, non-transformed cells, neoplastic cells, primary cultures of different cell types, and the like. Exemplary cells which can be employed in the practice of the present invention include Schneider cells, CV-1 cells, HuTu80 cells, F9 cells, NTERA2 cells, NB4

cells, HL-60 cells, 293 cells, Hela cells, yeast cells, and the like. Preferred host cells for use in the functional bioassay system are COS cells and CV-1 cells. COS-1 (referred to as COS) cells are monkey kidney cells that 5 express SV40 T antigen (Tag); while CV-1 cells do not express SV40 Tag. The presence of Tag in the COS-1 derivative lines allows the introduced expression plasmid to replicate and provides a relative increase in the amount of receptor produced during the assay period. CV-1 cells 10 are presently preferred because they are particularly convenient for gene transfer studies and provide a sensitive and well-described host cell system.

The above-described cells (or fractions thereof) are maintained under physiological conditions when 15 contacted with physiologically active compound. "Physiological conditions" are readily understood by those of skill in the art to comprise an isotonic, aqueous nutrient medium at a temperature of about 37°C.

Various constructs employed in the practice of 20 the present invention are well known in the art. Thus, the GAL4 DNA binding domain, the activation domain, GAL4 response elements and various members of the basal transcription machinery have all been well characterized and extensively discussed in the art. For example, the DNA 25 binding domain of the yeast GAL4 protein comprises at least the first 74 amino acids thereof (see, for example, Keegan et al., Science 231:699-704 (1986)). Preferably, the first 90 or more amino acids of the GAL4 protein will be used, with the first 147 amino acid residues of yeast GAL4 being 30 presently most preferred.

Activation domains contemplated for use in the practice of the present invention are well known in the art and can readily be identified by the artisan. Examples

include the GAL4 activation domain, BP64, VP16, and the like.

Exemplary GAL4 response elements are those containing the palindromic 17-mer:

5 5'-CGGAGGACTGTCCTCCG-3' (SEQ ID NO:2),

such as, for example, 17MX, as described by Webster et al., in Cell 52:169-178 (1988), as well as derivatives thereof. Additional examples of suitable response elements include those described by Hollenberg and Evans in Cell 55:899-906
10 10 (1988); or Webster et al. in Cell 54:199-207 (1988).

Exemplary reporter genes include chloramphenicol transferase (CAT), luciferase (LUC), beta-galactosidase (β -gal), and the like.

As used herein, the phrase "operatively associated with" means that the respective DNA sequences (represented, for example, by the terms "GAL4 response element" and "reporter gene") are operational, i.e., work for their intended purposes; the word "functionally" means that after the two segments are linked, upon appropriate activation by a ligand-receptor complex, the reporter gene will be expressed as the result of the fact that the corresponding "response element" was "turned on" or otherwise activated.

As readily recognized by those of skill in the art, the above-described assay can be modified to facilitate identification of compounds which disrupt any of the specific interactions involved in the formation of the above-described complex.

In accordance with yet another embodiment of the present invention, there are provided methods to identify compounds which disrupt complex comprising:

and optionally also activate said member, said method comprising:

10 (a) contacting a modified host cell with a test compound, wherein said modified host cell comprises:

15 a first fusion protein comprising an activation domain, operatively associated with at least one co-repressor,

20 a second fusion protein comprising a GAL4 DNA binding domain, operatively associated with a histone deacetylase,

25 a first reporter construct comprising a GAL4 response element operatively linked to a first reporter gene, and

30 a second reporter construct comprising a hormone response element operatively linked to a second reporter gene; and

25 (b) identifying those test compounds which cause reduced expression of the first reporter gene product and increased expression of the second reporter gene product as compounds which both disrupt said complex and activate said member, and

30 identifying those test compounds which cause reduced expression of the first reporter gene product, but substantially no

change in the level of expression of the second reporter gene product as compounds which disrupt said complex, but do not activate said member.

5 Those of skill in the art can readily determine suitable hormone response elements (HREs) for use in the practice of the present invention, such as, for example, the response elements described in United States Patent No. 5,091,518 and PCT published application no. WO 92/16546,
10 both of which are hereby incorporated by reference herein.

Naturally occurring HREs are composed of direct repeats (i.e., DRs; see Umesono et al., in Cell 65:1255-1266 (1991), inverted repeats (i.e., IRs; see Umesono et al., in Nature 336:262-265 (1988), and Williams et al. in
15 J. Biol. Chem. 266:19636-19644 (1991)), and/or everted repeats (ERs; see Baniahmad et al., in Cell 61:505-514 (1990); Farsetti et al., in J. Biol. Chem. 267:15784-15788 (1992); Raisher et al., in J. Biol. Chem. 267:20264-20269 (1992); or Tini et al., in Genes Dev. 7:295-307 (1993)) of
20 a degenerate X_n -AGGTCA core-site.

In direct repeats (DR, head-to-tail arrangement), the X_n sequence also serves as a gap which separates the two core-binding sites. Thus, for example, spacers of 1, 3, 4 and 5 nucleotides serve as preferred response elements for
25 heterodimers of RXR with PPAR, VDR, T₃R and RAR, respectively (see, for example, Naar et al., in Cell 65:1267-1279 (1991); Umesono et al., 1991, supra; Kliewer et al., in Nature 358:771-774 (1992); and Issemann et al.,
supra). The optimal gap length for each heterodimer is
30 determined by protein-protein contacts which appropriately position the DNA binding domains (DBDs) of RXR and its partner (see, for example, Kurokawa et al., in Genes Dev. 7:1423-1435 (1993); Perlmann et al., in Genes Dev. 7:1411-1422 (1993); Towers et al., in Proc. Natl. Acad. Sci. USA

90:6310-6314 (1993); and Zechel et al., in EMBO J. 13:1414-1424 (1994)).

Direct repeat hormone response elements (HREs) contemplated for use in the practice of the present invention are composed of at least one direct repeat of two or more half sites, optionally separated by one or more spacer nucleotides (with spacers of 1-5 preferred). The spacer nucleotides can be selected from any one of A, C, G or T. Each half site of direct repeat HREs contemplated for use in the practice of the invention comprises the sequence

-RGBNNM-,

wherein

R is selected from A or G;

15 B is selected from G, C, or T;

each N is independently selected from A, T, C, or G; and

M is selected from A or C;

with the proviso that at least 4 nucleotides of said -RGBNNM- sequence are identical with the nucleotides at corresponding positions of the sequence -AGGTCA-.

20 Response elements employed in the practice of the present invention can optionally be preceded by N_x , wherein x falls in the range of 0 up to 5.

25 In accordance with a still further aspect of the present invention, there are provided methods to identify compounds which prevent disruption of complex comprising:

(i) at least one co-repressor,

(ii) a histone deacetylase, and

30 (iii) a homodimer or heterodimer of a member of the steroid/thyroid superfamily of receptors,

said method comprising:

20

(a) contacting a modified host cell with a test compound in the presence of a ligand for said member of the steroid/thyroid superfamily of receptors, wherein said modified host cell comprises:

5

a first fusion protein comprising a GAL4 DNA binding domain (or, in an alternative an activation domain), operatively associated with at least one co-repressor,

10

a second fusion protein comprising an activation domain (or, in an alternative a GAL4 DNA binding domain), operatively associated with a histone deacetylase, and

15

a reporter construct comprising a GAL4 response element operatively linked to a reporter gene; and

(b) selecting those test compounds which prevent ligand-induced reduction of expression of the reporter gene product.

As readily understood by those of skill in the art, a wide variety of compounds can be assayed employing the invention method. Any compound with the potential to act as a ligand can be tested, e.g., steroid or steroid-like compounds, retinoids, thyroid hormones, pharmaceutically active compounds, naturally occurring compounds, synthetic organic compounds, and the like.

In accordance with yet another embodiment of the present invention, there are provided methods to identify compounds which disrupt complex comprising:

- (i) at least one co-repressor,
- (ii) a histone deacetylase, and

(iii) a homodimer or heterodimer of a member of the steroid/thyroid superfamily of receptors,

said method comprising:

5 (a) contacting an affinity matrix with a test compound, wherein said affinity matrix comprises:

an affinity support,

10 a first fusion protein comprising a member of the steroid/thyroid hormone superfamily of receptors, operatively associated with a glutathione-S-methionine (GST) label (or, in an alternative embodiment, a HIS label),

15 a second fusion protein comprising a heterologous partner for said member, operatively associated with a HIS label (or, in an alternative embodiment, a GST label), and

at least one co-repressor; and

20 (b) selecting those test compounds which cause the release of co-repressor from said support.

In accordance with still another embodiment of the present invention, there are provided methods to 25 identify modulators for members of the steroid/thyroid hormone superfamily of receptors, said method comprising:

30 (a) contacting a host cell with a co-repressor inhibitor and a test compound, wherein said host cell expresses said member of the steroid/thyroid hormone superfamily of receptors, and wherein said host cell optionally contains a reporter

construct comprising a hormone response element operatively linked to a reporter gene; and

5 (b) identifying as modulators those test compounds which modulate expression of gene product(s) under the control of said member.

The invention will now be described in greater detail by reference to the following non-limiting examples.

10

Example 1
SMRT has two independent repressor domains

The silencing activity of SMRT resides in the N-terminal half (amino acids 1-981) of the protein, while the receptor interaction domain (ID) is in the remaining C-terminal segment (Chen and Evans, Nature 377:454-457 15 (1995)). Minimal, transferable repressor domain(s) were identified in order to understand the mechanism of transcriptional repression and its molecular basis. Mammalian expression vectors expressing SMRT, SMRT 982-1495 (C-SMRT), SMRT 1-981 (N-SMRT), GAL4-SMRT, GAL4-SMRT 1-981, 20 GAL4-SMRT 982-1495, pCMX GAL4-DBD, pCMX-VP16, pMH100 TK-luc have been described previously (Chen and Evans, Nature 377:454-457 (1995)). SMRT-GAL4 constructs were generated by PCR amplification of the indicated regions and fused to GAL4 DNA binding domain (DBD) 1-147 (Figure 1A). Plasmids 25 were constructed by standard techniques.

Repressor activity was determined by transiently transfecting into CV-1 cells increasing amounts of the GAL4-fusion vectors along with a reporter construct pMH-100 TK-luc which contains 4 GAL4 binding sites. (Chakravarti 30 et al., Nature 383:99-103 (1996)). Fold repression was determined relative to the basal transcriptional activity

of the reporter in the presence of GAL4 DBD alone. Luciferase activity of each sample was normalized by the level of β -galactosidase activity. Each transfection was carried out in triplicate and repeated 3-6 times. Yeast 5 transformation and β -galactosidase activity assays were carried out in strain Y190 according to manufacturers protocol (Clonetech). The results of this assay are illustrated in Figure 1A.

SMRT 38-811 appears to be as potent a repressor 10 (45 fold) as either full length SMRT (35 fold) or SMRT 1-981 (30 fold), suggesting that in fact it contains all the domains necessary for full repression. Additional nested C-terminal deletions revealed a smaller though less potent repressor domain, SMRT 38-448 (12 fold). Further C-15 terminal deletions significantly lowered (38-370, 2.8 fold) and abolished (38-266) repressor activity. N-terminal deletions of SMRT 38-448 revealed that the minimal repressor domain resides between amino acids 259-448 (12-fold repression). Further deletions abolished the 20 repressor activity (364-448). Thus, amino acids 259-448 define an autonomous SMRT repressor domain (SRD-1).

That SRD-1 is a structural domain is supported by the observation that there were several sites susceptible to protease digestion by bacterial proteases in the 25 vicinity of the boundaries of SRD-1 (see Figure 1A arrows). Expanding SRD-1 towards the C-terminus (259-811) yielded a construct with increased repressor activity (100-fold) suggesting the presence of a second repressor domain. Additional deletions localized the boundary of a second, 30 autonomous minimal repressor domain between amino acids 559-657 (50 fold repression) which is termed SRD-2. SRD-1 and SRD-2 share substantial homology with the comparable region in N-CoR (42% and 39%, respectively) suggesting functional conservation.

Example 2
Interaction between SMRT and mSin3A

To explore the possibility of the existence of a SMRT-repressor complex that may involve mSin3A, several 5 protein based interaction assays were utilized. The yeast two-hybrid system was used to demonstrate functional association and to map the potential interface between SMRT and mSin3A (Figure 1B). The above-described fragments of SMRT fused to GAL4 DNA binding domain (GAL4-DBD, Example 1) 10 were co-transformed with GAL4 activation domain fused to mSin3A (AD-mSin3A) into yeast cells. β -galactosidase activity from 3 independent transformants was determined as described above (Example 1). When fused to mSin3A, the GAL4 activation domain (AD) gives a low background reporter 15 activity. However, in the presence of the GAL4 DNA binding domain (GAL4 DBD) fusion to intact SMRT (GAL4-SMRT), high reporter activity is observed, indicating a strong association between SMRT and mSin3A.

Utilizing a series of deletion mutants, 20 association with mSin3A was mapped to two regions of SMRT, amino acids 259-448, which correspond to SRD-1 and amino acids 449-657, which corresponds to SRD-2, respectively. Consistent with the domain mapping, further deletions (38- 214, 38-266, and 336-370) completely abolish association 25 with mSin3A. Therefore, these results suggest that the repressor activities of SRD1 and SRD2 are mediated via association with mSin3A.

A reciprocal set of experiments was conducted utilizing GAL4 DBD fusions of the SMRT repressor domain to 30 various deletions of mSin3A (Figure 1C). C-terminal deletions of mSin3A were fused to the GAL4 activation domain and co-transformed individually with either GAL4-SMRT (1-563) or GAL4-N-CoR (1016-1814) into yeast cells. β -galactosidase activity was determined as described above

(Example 1). Amino acid sequence 1-192 contains amphipathic helix (PAH) domain 1 (PAH1); 1-386 contains both PAH domains 1 and 2; 1-529 contains PAH domains 1, 2, and 3; and 1-965 contains all four PAH domains plus the 5 conserved linker between PAH 3 and 4.

These experiments show that PAH1 of mSin3A mediates interaction with SMRT while PAH2, 3 or 4 alone show no autonomous association. Inclusion of PAH1 and 2 results in a stronger association while addition of PAH3 10 shows no additional benefit. The strongest association is observed when all four PAHs are included. This indicates that SMRT makes extensive contacts with mSin3A. This is in contrast to Mad/Mxi-1 which selectively bind PAH2 via a 25 amino acid N-terminal segment.

15 The SMRT-related co-repressor, N-CoR, was also examined to determine if it associates with mSin3A via SRD-1 and SRD-2 related regions. While the boundaries of these regions have not been determined in detail, results indicate that N-CoR also interacts with mSin3A.

20

Example 3

A SMRT mSin-3A, HDAC 1 Ternary Complex

To determine if these interactions are direct, GST fusion proteins of 38-266, 38-448 and 548-811 of SMRT were examined for their ability to bind in vitro translated 25 35 S-Methionine-labeled mSin3A in pull down experiments. GST-SMRT 38-266, 38-448 and 548-811 were purified from E.coli cells and extracts were passed through a Glutathione Sepharose 4B affinity column (Pharmacia). Bound proteins were eluted with 15 mM glutathione. Purified proteins were 30 re-bound to Glutathione Sepharose beads and used as affinity matrices. In vitro translated, 35 S Methionine labeled mSin3A was incubated with GST, GST-SMRT 38-266 or GST-38-448. Only GST-SMRT-38-448 but not GST-SMRT 38-266

or GST alone pulls down radiolabeled mSin3A. These results suggest the existence of a direct physical interaction between SRD-1 and mSin3A.

mSin3A and B were compared for their ability to
5 interact with SRD-1. In vitro translated, ³⁵S Methionine labeled mSin3A, mSin3B and PAH domains of mSin3A (PAH1 (112-192), PAH1-2 (112-386), PAH1-3 (112-529), PAH1-4 (112-965) were used as probes in GST pull down experiments as described above with GST-SMRT 38-448 (S) or GST (G)). No
10 interaction was detected between SMRT and mSin3B under conditions in which mSin3A shows strong association. This experiment suggests that there may be a marked functional difference between the mSin3A and B isoforms.

Next, the region of mSin3A which mediates the
15 observed association with SRD-1 was determined. When radiolabeled PAH 1, 1-2 and 1-3 were tested in the same assay no apparent interaction was seen as with the yeast two-hybrid experiment. However, when all PAH domains (1-4) were included, strong interaction was observed.

Given that unliganded RAR/RXR heterodimers interact with SMRT and SMRT interacts with mSin3A, one would predict a hormone sensitive complex of all four proteins should form in vitro. To test this prediction, an affinity matrix consisting of GST-tagged RXR and His-tagged
20 RAR bound to glutathione beads was used in pull down experiments. GST-RXR LBD/6His RAR LBD was prepared from E.coli cells and purified by gel filtration chromatography through a Superdex S-200 column (Pharmacia). In vitro ³⁵[S]Methionine-labeled SMRT and mSin3A and B, and HDAC1
25 were synthesized using the indicated CMX plasmids as templates in a coupled transcription-translation system TNT (Promega). In vitro translated, ³⁵S-Methionine labeled SMRT was incubated with equal amounts of either GST or GST-RXR LBD/6 His-RAR LBD heterodimer in the absence or presence of

5 TM atRA. Radiolabeled GAL4-DBD fusion of PAH1-4 of mSin3A was incubated either with GST or GST-RXR LBD/6 His-RAR LBD heterodimer and labeled SMRT in the absence or presence of 5 TM all-trans retinoic acid (atRA) for 2h at
5 4°C. Bound proteins were eluted with 1X SDS PAGE buffer and separated on a 7.5 or 12.5 % SDS-PAGE. Gels were fixed, dried and exposed to film. Both mSin3A (PAH1-4) and SMRT are retained on the matrix in the absence of ligand and are released in a retinoic acid dependent fashion.

10 Genetic studies from yeast suggest that Sin3 repression can function through an Rpd3 dependent pathway (Stillman et al., *Genetics* 136:781-788 (1994)). Using GST fusions of SMRT 38-448 (SRD-1) and SMRT 548-811 (SRD-2) as affinity matrices, both SRD-1 and SRD-2 are able to form
15 ternary complexes with ³⁵S Methionine labeled mSin3A and HDAC1. Interestingly HDAC1 appears to interact more strongly with the SRD1/Sin3 complex than SRD2/Sin3. Together, these observations confirm that RAR/RXR heterodimers form a hormone-sensitive complex with SMRT,
20 HDAC1, and mSin3A.

Example 4

Functional interaction between HDAC1 and SMRT

If HDAC1 is a mediator of SMRT silencing, then direct recruitment of HDAC1 to a heterologous promoter
25 should result in repression of basal activity. This prediction was tested by fusing HDAC1 to the GAL4 DBD and assayed its effect on the basal activity of the GAL4-dependent reporter in transient transfection assays in CV-1 cells. The reporter gene contained GAL4 binding sites
30 upstream of a minimal TK promoter fused to luciferase gene (pMH100-TK-luc). Normalized luciferase activity was determined and fold repression (relative to GAL4-DBD alone) was calculated. Figure 2A shows that HDAC1-GAL4 is a potent repressor of transcriptional activation resulting in

a 60-fold repression of basal activity. Similar results were recently reported by Yang, W-M. et al., Nature 382:319-324 (1996) using mammalian homologs of Rpd3.

To test whether HDAC1 and SMRT form a complex in
5 mammalian cells, a fusion of SMRT 38-811 to the Herpes simplex VP16 activator domain was tested with HDAC1-GAL4 in a mammalian two-hybrid assay. Transient transfections were carried out (as described above) with a fixed (0.2 µg) amount of HDAC1-GAL4-DBD and increasing amounts of the VP-
10 fusion of SMRT 38-811. Figure 2B shows that as increasing amounts of VP-SMRT are co-expressed with HDAC1-GAL4, the transcriptional activity of the repressed promoter increases dramatically whereas VP-SMRT alone has no effect on the reporter alone or co-expressed with GAL4 DBD.
15 Activation above basal strongly supports the contention that VP-SMRT must be recruited to the promoter by HDAC1-GAL4 (Figure 2B). Transient transfection assays identical to the ones described above (see Figure 2B) were carried out with the indicated amounts of HDAC1-GAL4-DBD and VP-
20 SMRT 38-811 in the presence of increasing amount of SMRT (full length) or SMRT 982-1495 expression vectors.

As shown in Figure 2C, transfection of increasing amounts of full length SMRT displaces the VP-SMRT activator and re-establishes repression to an approximately 50% level
25 (lane 6). As a control, co-transfection of the carboxy terminal domain of SMRT fails to squelch the VP-SMRT/HDAC1 interaction. These results demonstrate both direct and functional association between HDAC1 and SMRT and demonstrates the strong repressive function of a promoter
30 tethered histone deacetylase.

Example 5Retinoic Acid and Trichostatin A Synergize in Cell Differentiation

If HDAC is a critical component of receptor function then addition of a deacetylase inhibitor, such as Trichostatin A (TSA) (Taunton et al., Science 272:408-411 (1996)) would be expected to relieve transcriptional repression, resulting in a promoter that is likely to be more sensitive to the addition of hormone. This prediction was tested by studying the effect of TSA on the differentiation of myeloid leukemia (HL-60) cells (Collins, Blood 70:1233-1244 (1987)) following a high dose (100 nM) 9-cis RA treatment. A hallmark of this process is the appearance of cell surface differentiation markers CD14 and CD11b (Brackman et al., Leukemia Research 19:57-64 (1995)). HL-60 cells cultured in RPMI 10% FBS were plated at a density of 2×10^5 /ml in RPMI 2 % FBS treated with 9-cis RA (Sigma) and/or Trichostatin A (TSA) (Waco Pure Chemical Industries) for 72 hours and then incubated with R-phycoerythrin (RPE) conjugated anti-human C3bi receptor (CD11b) (DAKO) or RPE-conjugated monoclonal mouse anti-human CD 14 (DAKO) antibodies for 60 minutes on ice. Cells were washed twice with PBS 0.5 % BSA and analyzed on a FACScan flow cytometer (Becton Dickinson). The expression of cell surface antigens (CD11b and CD14) were monitored.

100 nM TSA showed a minimal effect on the CD14 marker while a suboptimal dose (10 nM) of 9-cis RA resulted in modest stimulation (Fig. 3A). However, addition of both TSA and 10nM 9-cis RA resulted in dramatic enhancement of CD14 expression to levels higher than that following 100nM 9-cis RA treatment. Surprisingly the high dose 9-cis RA treatment was also enhanced by TSA. Similar results were seen with the CD11b marker, although in this case low doses of TSA partially activated gene expression (Fig. 3B). Again, the combination of TSA and 9-cis RA proved to be

cooperative at both high and low doses. While low levels of TSA were used to maintain dependence on retinoids for differentiation, a contribution to CD14/11b expression by other deacetylase sensitive factors cannot be excluded.

5 Nonetheless, this work supports a role for histone deacetylase in nuclear receptor signaling.

While the invention has been described in detail with reference to certain preferred embodiments thereof, it will be understood that modifications and variations are

10 within the spirit and scope of that which is described and claimed.

SEQUENCE LISTING

SEQ ID NO:1

Cys - X - X - Cys - X - X - Asp* - X - Ala* -
X - Gly* - X - Tyr* - X - X - X - X - Cys - X
- X - Cys - Lys* - X - Phe - Phe - X - Arg* -
X - X - X - X - X - X - X - X - (X - X -)
Cys - X - X - X - X - X - (X - X - X -) Cys - X -
X - X - Lys - X - X - Arg - X - X - Cys - X -
X - Cys - Arg* - X - X - Lys* - Cys - X - X - X
- Gly* - Met

SEQ ID NO:2

5' -CGGAGGACTG TCCTCCG-3'

That which is claimed is:

1. A method for the modulation of hormone mediated processes in a biological system, said method comprising contacting said system with an amount of a histone deacetylase inhibitor effective to modulate said 5 hormone mediated process.
2. A method according to claim 1 wherein said hormone mediated process is a retinoic acid receptor-mediated process or a thyroid hormone receptor mediated process.
3. A method according to claim 1 wherein said biological system is an intact organism.
4. A method according to claim 1 wherein said contacting is carried out by oral, intravenous, subcutaneous, intramuscular or intracutaneous mode of administration.
5. A method according to claim 1 wherein said histone deacetylase is HDAC 1 or Rpd3.
6. A method according to claim 1 wherein said system is contacted with a ligand in addition to said histone deacetylase inhibitor.
7. A composition comprising:
 - (a) a ligand for a member of the steroid/thyroid hormone superfamily of receptors, and
 - 5 (b) an inhibitor for co-repressor(s) which interact with said member of the steroid/thyroid hormone superfamily of receptors to suppress basal transcription activity in a pharmaceutically acceptable carrier therefor.

8. A composition according to claim 7 wherein said ligand is a ligand for a retinoid receptor or a thyroid hormone receptor.

9. A composition according to claim 7 wherein said inhibitor is a histone deacetylase inhibitor.

10. An isolated co-repressor complex comprising:

- (i) at least one co-repressor,
- (ii) a histone deacetylase, and
- (iii) a homodimer or heterodimer of a member of the steroid/thyroid superfamily of receptors.

5 11. A complex according to claim 10 wherein said co-repressor comprises a combination of SMRT and mSin3A.

12. A complex according to claim 10 wherein said member of the steroid/thyroid superfamily of receptors is a retinoid receptor or a thyroid hormone receptor.

13. A method to identify compounds which disrupt complex comprising:

- (i) at least one co-repressor,
- (ii) a histone deacetylase, and
- 5 (iii) a homodimer or heterodimer of a member of the steroid/thyroid superfamily of receptors,

said method comprising:

- 10 (a) contacting a modified host cell with a test compound, wherein said modified host cell comprises:

a first fusion protein comprising a GAL4 DNA binding domain, operatively associated with at least one co-repressor,

15 a second fusion protein comprising an activation domain, operatively associated with a histone deacetylase, and

 a reporter construct comprising a GAL4 response element operatively linked to a reporter gene; and

20 (b) selecting those test compounds which cause reduced expression of the reporter gene product.

14. A method to identify compounds which disrupt complex comprising:

5 (i) at least one co-repressor,
 (ii) a histone deacetylase, and
 (iii) a homodimer or heterodimer of a member of the steroid/thyroid superfamily of receptors,

said method comprising:

10 (a) contacting a modified host cell with a test compound, wherein said modified host cell comprises:

 a first fusion protein comprising an activation domain, operatively associated with at least one co-repressor,

15 a second fusion protein comprising a GAL4 DNA binding domain, operatively associated with a histone deacetylase, and

 a reporter construct comprising a GAL4 response element operatively linked to a reporter gene; and

20 (b) selecting those test compounds which cause reduced expression of the reporter gene product.

15. A method to identify compounds which prevent disruption of complex comprising:

- (i) at least one co-repressor,
- (ii) a histone deacetylase, and
- (iii) a homodimer or heterodimer of a member of the steroid/thyroid superfamily of receptors,

said method comprising:

16. A method to identify compounds which prevent disruption of complex comprising:

5

- (i) at least one co-repressor,
- (ii) a histone deacetylase, and
- (iii) a homodimer or heterodimer of a member of the steroid/thyroid superfamily of receptors,

said method comprising:

10

- (a) contacting a modified host cell with a test compound in the presence of a ligand for said member of the steroid/thyroid superfamily of receptors, wherein said modified host cell comprises:

15

a first fusion protein comprising an activation domain, operatively associated with at least one co-repressor,

20

a second fusion protein comprising a GAL4 DNA binding domain, operatively associated with a histone deacetylase, and a reporter construct comprising a GAL4 response element operatively linked to a reporter gene; and

- (b) selecting those test compounds which prevent ligand-induced reduction of expression of the reporter gene product.

17. A fusion protein comprising an activation domain operatively associated with a histone deacetylase.

18. A fusion protein comprising a GAL4 DNA binding domain operatively associated with a histone deacetylase.

19. A fusion protein comprising an activation domain operatively associated with mSin3A.

20. A fusion protein comprising a GAL4 DNA binding domain operatively associated with mSin3A.

21. A method to identify compounds which disrupt complex comprising:

(i) at least one co-repressor,

(ii) a histone deacetylase, and

5 (iii) a homodimer or heterodimer of a member of the steroid/thyroid superfamily of receptors,

said method comprising:

(a) contacting an affinity matrix with a test compound, wherein said affinity matrix comprises:

10 an affinity support,

a first fusion protein comprising a member of the steroid/thyroid hormone superfamily of receptors, operatively associated with a glutathione-S-methionine (GST) label,

15 a second fusion protein comprising a heterologous partner for said member, operatively associated with a HIS label, and
20 at least one co-repressor; and

(b) selecting those test compounds which cause the release of co-repressor from said support.

22. A method to identify compounds which disrupt complex comprising:

5

- (i) at least one co-repressor,
- (ii) a histone deacetylase, and
- (iii) a homodimer or heterodimer of a member of the steroid/thyroid superfamily of receptors,

said method comprising:

10

- (a) contacting an affinity matrix with a test compound, wherein said affinity matrix comprises:

15

- an affinity support,
 - a first fusion protein comprising a member of the steroid/thyroid hormone superfamily of receptors, operatively associated with a HIS label,

20

- a second fusion protein comprising a heterologous partner for said member, operatively associated with a glutathione-S-methionine (GST) label, and

- at least one co-repressor; and

- (b) selecting those test compounds which cause the release of co-repressor from said support.

23. A method to identify modulators for a member of the steroid/thyroid hormone superfamily of receptors, said method comprising:

5 (a) contacting a host cell with a co-repressor inhibitor and a test compound,
 wherein said host cell expresses said member of the steroid/thyroid hormone superfamily of receptors, and wherein said host cell optionally contains a reporter construct comprising a hormone response element operatively linked to a reporter gene; and
10
15 (b) identifying as modulators those test compounds which modulate expression of gene product(s) under the control of said member.

24. A method to identify compounds which disrupt complex comprising:

5 (i) at least one co-repressor,
 (ii) a histone deacetylase, and
 (iii) a homodimer or heterodimer of a member of the steroid/thyroid superfamily of receptors,

and optionally activate said member, said method comprising:

10 (a) contacting a modified host cell with a test compound, wherein said modified host cell comprises:
 a first fusion protein comprising an activation domain, operatively associated with at least one co-repressor,

15

a second fusion protein comprising a GAL4 DNA binding domain, operatively associated with a histone deacetylase,

20

a first reporter construct comprising a 4 response element operatively linked to a first reporter gene, and

a second reporter construct comprising a hormone response element operatively linked to a second reporter gene; and

25

(b) identifying those test compounds which cause reduced expression of the first reporter gene product and increased expression of the second reporter gene product as compounds which both disrupt said complex and activate said member, and

30

identifying those test compounds which cause reduced expression of the first reporter gene product, but substantially no change in the level of expression of the second reporter gene product as compounds which disrupt said complex, but do not activate said member.

35

1/9




FIG. IA

2/9




FIG. IB

3 / 9




FIG. IC

4 / 9




FIG. 2A

5/ 9




FIG. 2B

6 / 9




FIG. 2C

7/9




FIG. 3A

8 / 9




FIG. 3B




FIG. 3C

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/08569

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A 61K 38/02; A01N 37/18
US CL :514/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/02

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN ON LINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE BIOSIS on STN, AN 97:273471. GARCIA-VILLALBA P. et al. Histone acetylation influences thyroid hormone and retinoic acid-mediated gene expression. DNA and Cell Biology, 1997. Vol. 16, No. 4, pages 421-431	1,2,5 -----
Y	MITSUHASHI et al. n-Butyrate increases the level of thyroid hormone nuclear receptor. J. Biol. Chemistry, 1987, Vol. 262, No. 9, pages 3993-3999, see Abstract.	3,4,6-9
X	MAIYAR A. et al. Effect of sodium butyrate on 1,25-dihydrovitamin D3 receptor activity in primary chick kidney cells. Mol. Cell. Endocrinol., 1992, Vol. 84, pages 99-107, see Abstract	1,2,5 -----
Y		3,4,6

<input type="checkbox"/>	Further documents are listed in the continuation of Box C.	<input type="checkbox"/>	See patent family annex.
*	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"B"	earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"A"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search	Date of mailing of the international search report
14 JULY 1998	08 SEP 1998
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer <i>MICHAEL BORIN</i> Telephone No. (703) 305-4506

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/08569

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
1-9
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/08569

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claims 1-6, drawn to method of use of a histone deacetylase inhibitor.

Group II, claims 7-9, drawn to a composition comprising a receptor ligand and an inhibitor for co-repressor(s).

Group III, claims 10-12, drawn to co-repressor complex comprising co-repressor, histone deacetylase and a receptor.

Group IV, claims 13-14, drawn to method to identify compounds which disrupt complex of Group III using host cells modified with first and second fusion proteins.

Group V, claims 17-20, drawn to fusion protein.

Group VI, claims 15-16, drawn to method to identify compounds which prevent disruption of the complex of Group III using host cells modified with first and second fusion proteins.

Group VII, claims 21,22, drawn to method to identify compounds which disrupt complex of Group III using affinity matrix and labeled fusion proteins.

Group VIII, claim 23, drawn to method to identify receptor modulators using co-repressor inhibitor and a test compound.

Group IX, claim 24, drawn to method to identify compounds which disrupt complex of Group III and activate a receptor using host cells modified with first and second fusion proteins and first and second receptor constructs.

The inventions listed as Groups do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Group I is not the contribution over the prior art because it is suggested by references teaching modulation of hormone-mediated processes by histone deacetylase inhibitor. For example, such effect of modulation of hormone-mediated processes by histone deacetylase inhibitor is taught by Mitsuhashi et al (J. Biol. Chem., 262(9),3993-3999, 1987). Therefore, the lack of unity is present because the linking technical feature is not a "special technical feature" as defined by PCT Rule 13.2.